Chronic hepatitis C virus (HCV) infection is a worldwide public health problem with a global prevalence of 2-3%[@B1]. In addition to being a frequent cause of chronic liver diseases such as hepatitis, cirrhosis, and hepatocellular carcinoma, it is also involved in the pathogenesis of various autoimmune and rheumatic disorders such as arthritis, vasculitis, sicca syndrome, porphyria cutanea tarda, lichen planus, nephropathies, thyroid diseases, lung fibrosis, among others[@B1] ^,^ [@B2] ^,^ [@B3]. Even though the rheumatic disorders are common among the extrahepatic manifestations, the mechanisms involved in the onset of these symptoms as well as the associated genetic factors are yet to be understood completely.

Host genetic factors such as the the human platelet antigens (HPA) polymorphism are also known to be associated with the infection and persistence of HCV[@B4] ^,^ [@B5]. However, there is no evidence of its relation to rheumatological manifestations.

HPAs result from the polymorphisms in the genes encoding surface glycoproteins of platelets, endothelial cells, and fibroblasts[@B6] ^,^ [@B7], and are commonly involved in rheumatological diseases. Considering that the fibroblasts express HPA, these proteins could be involved in rheumatological manifestations. Thus, the aim of this study was to verify associations between allele and genotype HPA-1, -3, and -5 polymorphisms and rheumatological manifestations in patients with chronic hepatitis C.

A total of 159 individuals aged between 18 and 80 years, of both genders and affected by chronic hepatitis C, assisted at the Viral Hepatitis Outpatient Clinic of Botucatu Medical School, Unesp, Brazil, were included in this study. We only considered detectable HCV-RNA cases, with identification of HCV genotype, no previous hepatitis C treatment (*naïve* patients), with known fibrosis stage or clinical diagnosis of cirrhosis by image. Patients with HBV/HIV co-infection, chronic renal insufficiency, liver or renal transplantation, liver diseases, and other diffuse connective tissue diseases, including rheumatoid arthritis, according to Rheumatoid Arthritis Classification Criteria (ACR-EULAR 2010), were excluded[@B8].

Clinical symptoms, such as presence of paresthesia sensations, Raynaud\'s phenomenon, cutaneous alterations, subcutaneous nodule, myalgia, muscle weakness, non-mechanical low back pain, arthralgia, arthritis, and other rheumatological manifestations were considered as rheumatological manifestations in this study. Laboratorial parameters evaluated were rheumatoid factor (qualitative and semi-quantitative) and anti-CCP (semi-quantitative) using Reumalatex kit (Labtest Diagnostica S/A, Lagoa Santa, MG, Brazil) and QUANTA LiteTM CCP3.1 kit (INOVA Diagnostic Inc., San Diego, CA, USA), respectively, according to the manufacturer's instructions.

Deoxyribonucleic acid (DNA) was isolated from the total blood using the Wizard^®^ Minipreps DNA Purification System and used to genotype HPA-1 and HPA-3 with polymerase chain reaction-sequence-specific primers (PCR-SSP), as described by Klüter et al[@B9]. HPA-5 was genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), as described by Kalb et al[@B10].

The association analysis between the categorical variables was performed using the χ^2^ or Fisher's exact test. Student\'s t-test was used for comparing the mean ages. Logistic regression was used to categorize the risk of the association among the groups. Odds ratio values with 95% conﬁdence interval were also calculated. *P*≤ 0.05 was considered statistically significant.

This study was approved by the Ethics Committee on Research of Sao Paulo State University (Protocol 3727/2010), and conforms to the provisions of Helsinki Declaration of 1964, as revised in 1975, 1983, 1989, 1996, and 2000. All the participants of this study signed the individually informed consent forms.

Out of 159 individuals, 87 (54.7%) were men and 72 (45.3%) were women. The median and mean ages were 49 years (24 to 76 years) and 48.7 years, respectively.

Rheumatological manifestations were present in 72.3% of the patients. [Table 1](#t1){ref-type="table"} shows the demographic and clinical characteristics related to rheumatic involvement. An association between female gender and development of rheumatological manifestations (*P* = 0.0201) was observed. This association was maintained when the data was subjected to multivariate logistic regression analysis (*P* = 0.0381). It is well-known that the rheumatic diseases are more prevalent in women, regardless of other concomitant clinical conditions[@B11]. The correlation between rheumatic manifestation and female gender was already observed in a research conducted with Egyptian population affected by chronic hepatitis C[@B12]. In addition, Cacoub et al[@B13] showed that more than 70% of the HCV-infected patients showed extrahepatic manifestations involving primarily joints, muscles, and skin, which as per our findings, were also associated to female gender.

TABLE 1:Clinical and demographic characteristics of the population with chronic hepatitis C, distributed by presence or absence of rheumatological manifestations.VariablesPresence of rheumatologicalAbsence of rheumatological*P-value*manifestationsmanifestationsn = 115 (%)n = 44 (%)Age (years), mean49.6 ± 10.046.3 ± 10.30.0672^†^**Sex**Male56 (64.4)31 (35.6)0.0201Female59 (81.9)13 (18.1)**Ethnicity**White102 (72.3)39 (27.7)1.0000Non-white13 (72.2)5 (27.8)HCV Genotype180 (73.4)29 (26.6)0.7042Not 135 (70.0)15 (30.0)Fibrosis^‡^Absent (F0)3 (75.0)1 (25.0)0.0519Moderate (F1, F2)48 (64.0)27 (36.0)Advanced (F3)20 (69.09 (31.0)Cirrhosis44 (86.3)7 (13.7)[^3]

Genotype and allele frequencies of HPA-1, -3, and -5 were distributed according to the presence or absence of rheumatological manifestations. There was no significant association observed among the patients. However, upon considering the gender ([Table 2](#t2){ref-type="table"} and [Table 3](#t3){ref-type="table"}), the females showed a significant association between rheumatological manifestation and allele HPA-3a (OR = 3.83, 95% CI = 1.60-9.22, and *P* = 0.0044) and HPA-3a3a (OR = 6.98, 95% CI = 1.42-34.31, and *P* = 0.0125). Moreover, a risk was also observed for HPA-1a1b (OR = 7.67, 95% CI = 0.93-63.02, and *P* = 0.0482). On the contrary, HPA-3b3b was protective (OR = 0.21, 95% CI = 0.47-0.93, and *P* = 0.0496) for rheumatological manifestations.

TABLE 2:Genotype and allele frequencies of HPA-1, -3, and -5 in women with chronic hepatitis C, distributed by the presence and absence of rheumatological manifestations.HPAPresence ofAbsence ofStatistical Analysisrheumatologicalrheumatologicalmanifestationsmanifestations**Alleles2n = 118 (%)2n = 26 (%)OR (CI 95%)*P-value***1a93 (80.2)23 (19.8)0.49 (0.13 - 1.75)0.41111b25 (89.3)3 (10.7)2.06 (0.57 - 7.43)3a87 (88.8)11 (11.2)3.83 (1.60 - 9.22)0.00443b31 (67.4)15 (32.6)0.26 (0.11 - 0.63)5a99 (79.8)25 ( 20.2)0.21 (0.03 - 1.63)0.12575b19 (95.0)1 (5.0)4.80 (0.61 - 37.60)**Genotypesn = 58 (%)n = 13 (%)OR (CI 95%)*P-value***1a/1a35 (76.0)11 (24.0)0.27 (0.05 - 1.31)0.11551a/1b23 (95.8)1 (4.2)7.67 (0.93 - 63.02)0.04821b/1b1 (50.0)1 (50.0)0.21 (0.01 - 3.55)0.33063a/3a33 (94.3)2 (5.7)6.98 (1.42 - 34.31)0.01253a/3b21 (75.0)7 (25.0)0.47 (0.14 - 1.60)0.34603b/3b5 (55.6)4 (44.4)0.21 (0.47 - 0.93)0.04965a/5a42 (77.8)12 (22.2)0.21 (0.03 - 1.71)0.16285a/5b15 (93.8)1 (6.2)4.09 (0.49 - 34.20)0.27235b/5b2 (100.0)0 (0)1.17 (0.05 - 25.91)1.0000[^4]

TABLE 3:Genotype and allele frequencies of HPA-1, -3, and -5 in men with chronic hepatitis C, distributed by the presence and absence of rheumatological manifestations.HPAPresence ofAbsence ofStatistical Analysisrheumatologicalrheumatologicalmanifestationsmanifestations**Alleles2n = 112 (%)2n = 62 (%)OR (CI 95%)*P-value***1a97 (66.4)49 (33.6)1.72 (0.76 - 3.90)0.20301b15 (53.6)13 (46.4)0.58 (0.26 - 1.32)3a76 (62.8)45 (37.2)0.80 (0.40 - 1.58)0.60673b36 (67.9)17 (32.1)1.25 (0.63 - 2.50)5a99 (64.7)54 (35.3)1.13 (0.44 - 2.89)0.81155b13 (61.9)8 (38.1)0.89 (0.35 - 2.27)**Genotypesn = 56 (%)n = 31 (%)OR (CI 95%)*P-value***1a/1a44 (69.8)19 (30.2)2.32 (0.88 - 6.08)0.13181a/1b9 (45.0)11 (55.0)0.35 (0.13 - 0.97)0.06121b/1b3 (75.0)1 (25.0)1.70 (0.17 - 17.07)1.00003a/3a26 (63.4)15 (36.6)0.92 (0.38 - 2.23)1.00003a/3b24 (61.5)15 (38.5)0.80 (0.33 - 1.93)0.65773b/3b6 (85.7)1 (14.3)3.60 (0.41 - 31.39)0.41355a/5a44 (65.7)23 (34.3)1.28 (0.46 - 3.56)0.79085a/5b11 (57.9)8 (42.1)0.70 (0.25 - 1.99)0.59075b/5b1 (100.0)0 (0)1.70 (0.07 - 43.09)1.0000[^5]

In this context, it is noteworthy that HPA-1 and HPA-3 are located in the same glycoprotein complex (GPIIb-IIIa) expressed in both endothelial cells and fibroblasts[@B7], which are the cells commonly involved in rheumatological diseases. However, additional studies involving other populations are necessary to confirm these data and to improve the understanding of the mechanisms involved in rheumatic manifestations in chronic HCV infection. Similar to the well-established association of human leukocyte antigens (HLA) and diseases, studies involving HPA may also contribute towards the identification of clinically important molecular markers, thereby aiding in understanding the pathophysiological mechanisms involved in the diseases.

Our study is the first report of a strong association between rheumatological manifestations and HPA-3 polymorphism, which may explain the possible predisposition of women to complications during the course of chronic hepatitis C.
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